查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2017218

血液培养检测市场：2026-2032年全球市场预测（依产品类型、技术、检测类型、检体类型、实施方法、最终用户和应用划分）

Blood Culture Test Market by Product, Technology, Test Type, Sample Type, Mode, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年血液培养检测市场价值为56.7亿美元，预计到2026年将成长至60.3亿美元，复合年增长率为7.19%，到2032年将达到92.3亿美元。

主要市场统计数据
基准年 2025 56.7亿美元
预计年份：2026年 60.3亿美元
预测年份 2032 92.3亿美元
复合年增长率 (%) 7.19%

简要概述血液培养诊断在现代医疗保健服务体系中不断发展的临床和运作重要性。

血液培养检测仍是诊断血流感染疾病和指南抗生素治疗的基本诊断程序。儘管培养系统、自动化和分子辅助技术的进步提高了血液培养工作流程的临床效用和操作效率，但检查室仍在不断努力平衡检体处理的速度、敏感度和成本。在临床实践中，及时检测能够直接影响患者预后，因为它有助于标靶治疗方案并减少不必要的抗生素暴露，因此血液培养能力是急诊过程中不可或缺的一部分。

创新、自动化、供应链韧性和诊断管理如何共同改变血液培养检测中的检查室工作流程和临床路径。

受技术创新、工作流程优化以及检查室在诊疗路径中角色重新定义的推动，血液感染疾病的诊断方法正在经历一场变革。儘管传统的培养技术仍然能够提供重要的表型信息，但分子诊断平台和快速鑑定方法正在拓展临床医生的工具箱，使他们能够更早地减少经验性治疗，并提高抗生素的合理使用。技术的多元化促使检查室重新思考其检测流程，并采用能够互补地利用培养和分子诊断优势的混合方法。

评估关税对血液培养诊断领域的成本结构、采购决策和分销模式造成的采购挑战和供应链策略影响。

近期关税趋势和贸易政策调整对参与血液培养诊断的临床检查室、製造商和经销商产生了显着的下游影响。某些检测设备和耗材进口关税的提高可能会增加接收成本，迫使采购团队重新评估其供应商组合，并协商长期合约以稳定价格。为此，製造商可能会考虑透过地理多元化生产、替代筹资策略或调整产品组合来降低关税风险，同时维持其利润结构。

综合細項分析，概述产品、最终用户、技术、测试类型、应用、检体类型和实施方法对产品采用和采购趋势的影响。

对各类产品类型的详细分析揭示了耗材和仪器的具体考虑因素，这些因素会影响产品的采用和采购决策。耗材，包括试管、培养基和试剂组，是持续营运成本的组成部分，需要评估其批次间一致性、储存需求以及与自动化系统的兼容性。仪器，例如分析仪器和自动化系统，则需要进行资本规划、与实验室资讯系统 (LIS) 整合以及签订长期服务合约。因此，采购决策通常图在耗材供应的可预测性与引入分析仪器所带来的效率提升和验证负担之间取得平衡。

影响美洲、欧洲、中东和非洲以及亚太地区技术采用、采购偏好和服务模式的区域趋势和基础设施因素。

地理趋势导緻美洲、欧洲、中东和非洲以及亚太地区的需求驱动因素和营运限制各不相同，这反映了各地区独特的医疗基础设施、报销模式和区域供应链结构。在美洲，大规模的综合医疗体系和对诊断管理的重视促使人们倾向于高通量自动化和互联互通，而独立实验室则推动了分散式服务模式的发展。在欧洲、中东和非洲，监管协调、多样化的采购框架和基础设施的异质性并存，这为能够应对不同临床环境的模组化解决方案创造了机会。在亚太地区，快速发展的实验室网路与成熟的高效中心并存，使得人们对可扩展的自动化和分子诊断支援技术产生了浓厚的兴趣，以应对地方性感染和医院获得性感染的挑战。

竞争优势源自于一体化的解决方案组合、强大的服务网络以及与检查室工作流程和临床重点一致的有针对性的创新。

在血液培养检测生态系统中，产品可靠性、整合能力和服务卓越性是企业获得竞争优势的关键。拥有从耗材到仪器等广泛产品组合的领导企业，能够提供端到端的解决方案，从而降低供应商管理的复杂性，并建立无缝的工作流程，进而获得竞争优势。那些投资于互通性、数据整合和以用户为中心的设计，以最大限度地减少人工操作时间并简化结果报告流程的企业，能够增强其对高通量检查室和医院系统的价值提案。同时，专注于快速分子鑑定和高灵敏度检测等细分技术领域的专业公司，可以在将先进诊断视为优先事项的参考中心和三级医疗机构中占据战略地位。

为供应商和检查室管理人员提供可操作的策略重点，以提高诊断价值、营运弹性和以合作伙伴为中心的商业化模式。

产业领导者若想巩固市场地位并提升临床影响力，应围绕两大目标进行投资：提高诊断价值和增强营运韧性。首先，应优先考虑能够连接表型培养和快速分子鑑定的解决方案，以便在现有检测流程的限制下提供临床可用的结果。这使得机构能够在满足下游流程中表型药敏试验需求的同时，及时向临床医师提供资讯。其次，应投资于自动化和资讯技术，以减少人为操作差异并缩短检测结果报告时间，并确保建立完善的培训和检验机制，从而确保这些技术的成功应用。

采用严谨的混合方法研究途径，结合对从业者的访谈、技术文献和检验程序，得出可操作和可重复的诊断见解。

本研究采用混合方法，整合了与血液培养诊断相关的临床、商业性和营运方面的见解。主要资讯来源包括对实验室管理人员、采购负责人和临床微生物学家的结构化访谈，以深入了解工作流程的限制、检验实践和临床应用案例。二级资讯来源包括同行评审文献、监管指南和製造商技术文檔，以确保符合现行标准和性能要求。分析结合了定性主题整合和跨产品类型、最终用户、技术和地区的横断面比较，以识别一致的模式和差异化因素。

整合临床、营运和策略要求，指导血液培养诊断解决方案的有效实施和永续部署。

血液培养诊断正处于变革的关键时期，随着技术创新、供应链考量和临床需求的融合，检查室的运作方式正在重塑。儘管传统的培养系统仍然是表型药敏试验的核心，但分子诊断和自动化辅助技术正在重新定义人们对速度和诊断准确性的期望。这些互补的方法为混合诊断路径创造了机会，从而在快速鑑定和全面药敏评估之间取得平衡，进而改善药物使用和患者预后。在营运方面，检查室在实施新平台时必须应对价格调整、供应链波动以及整合和检验要求带来的成本压力。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 血液培养检测市场：依产品划分

  • 消耗品
    • 瓶子
    • 培养基
    • 试剂组
  • 装置
    • 分析器
    • 自动化系统

第九章 血液培养检测市场：依技术划分

  • 传统的
  • 分子
    • 次世代定序
    • 聚合酵素链锁反应

第十章 血液培养检测市场（依检测类型划分）

  • 自动的
  • 手动的

第十一章 依检体类型分類的血液培养检测市场

  • 电浆
  • 全血

第十二章 依实施方式分類的血液培养检测市场

  • 中心检查室
  • 护理点
    • 床头
    • 携带式的

第十三章 血液培养检测市场：依最终用户划分

  • 门诊部
    • 独立诊所
    • 私人诊所
  • 血库
  • 诊断检查室
    • 医院检查室
    • 独立检测实验室
  • 医院和诊所
    • 二级医院
    • 三级医疗机构

第十四章 血液培养检测市场：依应用领域划分

  • 细菌
    • 革兰氏阴性菌
    • 革兰氏阳性菌
  • 真菌
    • 丝状真菌
    • 酵母菌
  • 分枝桿菌

第十五章 血液培养检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 血液培养检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 血液培养检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国血液培养检测市场

第十九章：中国血液培养检测市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Accelerate Diagnostics, Inc.
  • Autobio Diagnostics Co. Ltd.
  • Becton Dickinson and Company
  • bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • F. Hoffmann-La Roche
  • Siemens Healthineers AG
  • Sigma-Aldrich
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-035DA3C63737

The Blood Culture Test Market was valued at USD 5.67 billion in 2025 and is projected to grow to USD 6.03 billion in 2026, with a CAGR of 7.19%, reaching USD 9.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.67 billion
Estimated Year [2026] USD 6.03 billion
Forecast Year [2032] USD 9.23 billion
CAGR (%) 7.19%

A concise orientation to the evolving clinical and operational significance of blood culture diagnostics within modern healthcare delivery systems

Blood culture testing remains a foundational diagnostic procedure for detecting bloodstream infections and guiding antimicrobial therapy. Advances in culture systems, automation, and molecular adjuncts have increased the clinical relevance and operational throughput of blood culture workflows, while laboratories continually balance speed, sensitivity, and cost in specimen processing. In clinical settings, timely detection directly influences patient outcomes by informing targeted therapy and reducing inappropriate antimicrobial exposure, making blood culture capability a critical component of acute care pathways.

In parallel, laboratory managers and procurement specialists must navigate a landscape shaped by technology convergence, supply chain dynamics, and evolving regulatory expectations. The integration of automated analyzers with front-end specimen handling and data connectivity has improved consistency and reduced hands-on time, yet it has also introduced new vendor interoperability and validation considerations. As healthcare systems prioritize diagnostic stewardship and laboratory efficiency, blood culture testing is experiencing both operational refinement and strategic reassessment across hospital systems, independent laboratories, and outpatient facilities.

This executive summary synthesizes current dynamics affecting clinical practice, technology adoption, and organizational investment decisions. It highlights how shifts in diagnostic paradigms, policy environments, and end-user requirements are reshaping procurement preferences and implementation strategies, with implications for clinical laboratories, device manufacturers, and healthcare administrators seeking to optimize diagnostic value across care continuums.

How innovation, automation, supply chain resilience, and diagnostic stewardship are jointly reshaping laboratory workflows and clinical pathways in blood culture testing

The diagnostic landscape for bloodstream infection detection is undergoing transformative shifts driven by technological innovation, workflow optimization, and a reimagining of laboratory roles within care pathways. Conventional culture techniques continue to provide essential phenotypic information, yet molecular platforms and rapid identification methods have expanded the clinician's toolkit, enabling earlier de-escalation of empiric therapy and enhanced antimicrobial stewardship. This technological diversification has prompted laboratories to re-evaluate test algorithms and to adopt hybrid approaches that leverage both culture and molecular modalities for complementary strengths.

Operationally, increased adoption of automation across pre-analytical and analytical stages is altering laboratory staffing models and throughput expectations. Automation reduces manual variability and supports higher sample volumes, but it also necessitates investments in training, validation, and informatics to ensure seamless integration. At the same time, supply chain resilience has emerged as a strategic priority. Laboratories and suppliers are exploring redundancy in sourcing consumables and diversifying logistics to mitigate disruptions, which in turn affects procurement cycles and inventory management practices.

Clinically, there is an intensified focus on diagnostic stewardship, driven by payer scrutiny and institutional quality initiatives. Diagnostic pathways are being redesigned to emphasize timely and accurate detection while avoiding unnecessary testing. This shift influences adoption patterns for both automated and manual testing modalities and underscores the importance of actionable reporting, result turnaround time, and linkage to clinical decision support systems. Taken together, these trends are not only reshaping laboratory operations but also creating new opportunities for vendors and health systems to collaborate on integrated solutions that deliver measurable clinical and economic value.

Assessment of tariff-driven procurement stressors and supply chain strategies that are influencing cost structures, sourcing decisions, and distribution models across blood culture diagnostics

Recent tariff developments and trade policy adjustments have created material downstream effects for clinical laboratories, manufacturers, and distributors involved in blood culture diagnostics. Increased import duties on certain laboratory equipment and consumables can raise landed costs, prompting procurement teams to reassess supplier portfolios and negotiate longer-term contracts to stabilize pricing. In response, manufacturers may explore regionalization of production, alternative sourcing strategies, or changes to product configurations to mitigate tariff exposure while preserving margin structures.

These dynamics influence procurement behavior across end users, with hospitals and independent laboratories weighing the trade-offs between unit cost, reliability of supply, and vendor support commitments. Some organizations may prioritize stocking larger inventories of critical consumables to buffer against price volatility, while others will seek service models that reduce capital expenditure and transfer supply risk to vendors through managed services or reagent-rental agreements. Moreover, increased costs can accelerate interest in automation and workflow efficiency initiatives as organizations seek to offset higher per-unit prices through labor savings and reduced waste.

At the same time, regulatory and customs complexities associated with tariff implementation can extend lead times and complicate product launch strategies for new analyzers and consumables. Manufacturers and distributors are therefore adapting distribution and logistics frameworks, enhancing visibility across supply chains, and collaborating with customers to develop contingency plans. Collectively, these changes encourage more strategic procurement planning, foster supplier diversification, and create incentives for supply chain transparency and regional manufacturing investment to reduce the cumulative impact of tariff-related cost pressures.

Integrated segmentation analysis outlining product, end-user, technological, test-type, application, sample type, and mode implications that shape adoption and procurement dynamics

A granular view across product categories reveals distinct considerations for consumables and instruments that shape adoption and purchasing behavior. Consumables, encompassing bottles, culture media, and reagent kits, drive recurring operating cost and are evaluated for lot-to-lot consistency, storage requirements, and compatibility with automated systems. Instruments, including analyzers and automation systems, require capital planning, integration with laboratory information systems, and long-term service agreements. Consequently, buying decisions often balance the predictability of consumable supply against the efficiency gains and validation burden associated with analyzer deployment.

End-user segmentation highlights that ambulatory care centers, blood banks, diagnostic laboratories, and hospitals and clinics each follow different operational models and procurement imperatives. Ambulatory care delivery is typically split between independent clinics and physician offices, which prioritize ease of use and compact footprint. Blood banks emphasize reliability and regulatory compliance, whereas diagnostic laboratories - including hospital-based labs and independent labs - focus on throughput, turnaround time, and interoperability. Secondary and tertiary hospitals within the hospital and clinic segment demand scalable solutions, with tertiary centers often integrating advanced identification technologies.

Technology choices between conventional and molecular methods determine diagnostic pathways. Conventional culture remains essential for susceptibility testing and phenotypic confirmation, while molecular approaches, such as next generation sequencing and polymerase chain reaction, are increasingly used for rapid identification and characterization in complex cases. Test type preferences between automated and manual workflows reflect institutional priorities: automated platforms favor consistency and reduced hands-on time, whereas manual testing may persist in low-volume or resource-constrained settings. Application-specific requirements further differentiate use cases, with bacterial testing divided into gram-negative and gram-positive targets, fungal testing addressing filamentous fungi and yeast, and mycobacterial assays requiring specialized processing. Sample type considerations between plasma and whole blood influence processing protocols and instrument compatibility, and mode of delivery, whether central laboratory or point of care, including bedside and portable options, drives decisions about decentralization versus consolidated testing capacity. Together, these segmentation lenses provide a multidimensional framework for aligning product development, commercialization, and clinical implementation strategies.

Regional dynamics and infrastructure factors that steer technology adoption, procurement preferences, and service models across the Americas, Europe Middle East & Africa, and Asia-Pacific landscapes

Geographic dynamics create differentiated demand drivers and operational constraints across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions, each reflecting unique healthcare infrastructure, reimbursement models, and regional supply chain architectures. In the Americas, large integrated healthcare systems and a focus on diagnostic stewardship influence preferences for high-throughput automation and connectivity, while independent laboratories drive decentralized service provision. Within Europe, Middle East & Africa, regulatory harmonization efforts coexist with varied purchasing frameworks and infrastructure heterogeneity, creating opportunities for modular solutions that accommodate diverse clinical settings. The Asia-Pacific region presents a mix of rapidly developing laboratory networks alongside mature centers of excellence, with considerable interest in scalable automation and molecular adjuncts to address both endemic and hospital-acquired infection challenges.

Regional procurement strategies differ in how they balance capital investment with operational expenditures. In well-capitalized systems, there is often appetite for advanced analyzers and integrated automation to support high-volume workflows, whereas in regions with resource constraints, manual or semi-automated approaches and durable consumables retain relevance. Cross-border logistics and tariff regimes further shape distribution strategies, prompting vendors and health systems to consider regional warehousing, local partnerships, and flexible service models to maintain supply reliability. Importantly, clinical priorities such as antimicrobial resistance surveillance, sepsis management programs, and public health reporting influence uptake of specific technologies and assays, leading to regionally tailored product roadmaps and support services that align with local clinical imperatives.

Competitive differentiation emerges from integrated solution portfolios, robust service networks, and targeted innovations that align with laboratory workflows and clinical priorities

Competitive positioning in the blood culture testing ecosystem is shaped by companies that excel in product reliability, integration capabilities, and service excellence. Leaders with broad portfolios across consumables and instrumentation gain advantage by offering end-to-end solutions that reduce the complexity of supplier management and validate seamless workflows. Organizations that invest in interoperability, data integration, and user-centered design to minimize hands-on time and streamline result reporting strengthen their value proposition to high-volume laboratories and hospital systems. Conversely, specialized companies that focus on niche technology areas-such as rapid molecular identification or high-sensitivity detection-can secure strategic placements within reference centers and tertiary institutions where advanced diagnostics are prioritized.

Partnership strategies and channel models also differentiate competitive approaches. Firms that cultivate robust distributor networks and local technical support are better positioned to serve diverse geographies, while those that offer embedded service programs, reagent-rental options, or outcome-linked contracting can alleviate capital constraints for customers. Additionally, companies that demonstrate supply chain transparency and responsiveness during periods of disruption build trust and long-term relationships with institutional buyers. Innovation pipelines that integrate automation, molecular adjuncts, and digital reporting capabilities offer incremental clinical and operational benefits, and organizations that align R&D investments with real-world laboratory workflows will likely secure preferential consideration in procurement decisions.

Ultimately, company success is increasingly tied to the ability to deliver demonstrable operational efficiencies, regulatory-compliant performance, and scalable support models that align with the clinical and financial objectives of diverse laboratory customers.

Actionable strategic priorities for vendors and laboratory leaders to enhance diagnostic value, operational resilience, and partner-focused commercialization models

Industry leaders seeking to strengthen market position and clinical impact should align investments with the twin objectives of improving diagnostic value and enhancing operational resilience. First, prioritize solutions that bridge phenotypic culture and rapid molecular identification to deliver clinically actionable results within the constraints of existing laboratory workflows. By doing so, organizations can support clinicians with timely information while preserving the downstream need for phenotypic susceptibility testing. Second, invest in automation and informatics that reduce manual variability and shorten turnaround times, ensuring that technology deployments are accompanied by robust training and validation programs to secure adoption.

Third, build supply chain flexibility through diversified sourcing, regional warehousing, and transparent inventory management. Such measures reduce vulnerability to tariff-induced cost shifts and logistical bottlenecks. Fourth, engage end users through outcome-focused service offerings, including reagent-rental models, managed reagent programs, and performance-based contracting that align vendor incentives with laboratory throughput and quality objectives. Fifth, pursue partnerships with clinical teams to embed diagnostic stewardship principles into testing algorithms and reporting formats, thereby strengthening the linkage between laboratory outputs and therapeutic decision-making. Finally, incorporate scalability into product design so that solutions are adaptable across ambulatory centers, blood banks, reference labs, and hospital systems, supporting phased upgrades and modular deployments that match capital cycles and clinical demand.

A rigorous mixed-methods research approach combining practitioner interviews, technical literature, and validation steps to produce actionable and reproducible diagnostic insights

This research employed a mixed-methods approach to synthesize clinical, commercial, and operational insights relevant to blood culture diagnostics. Primary inputs included structured interviews with laboratory directors, procurement officers, and clinical microbiologists, providing contextual understanding of workflow constraints, validation practices, and clinical use cases. Secondary sources comprised peer-reviewed literature, regulatory guidance, and manufacturer technical documentation to ensure alignment with current standards and performance expectations. The analysis integrated qualitative thematic synthesis with cross-sectional comparisons across product categories, end users, technologies, and geographic regions to identify consistent patterns and differentiated drivers.

To enhance reliability, findings were triangulated through multiple data streams and validated against practitioner feedback during expert review sessions. Methodological safeguards included explicit documentation of inclusion criteria for literature and technical documents, and careful delineation of technology definitions to distinguish conventional culture processes from molecular adjuncts. The approach prioritized reproducibility by outlining data sources, interview protocols, and analytic frameworks, enabling stakeholders to interrogate assumptions and adapt insights to their specific operational contexts. While this synthesis emphasizes practical implications, it remains grounded in established laboratory practice and contemporary diagnostic trends, providing a credible foundation for strategic planning and operational optimization.

Synthesis of clinical, operational, and strategic imperatives that converge to guide effective adoption and sustainable deployment of blood culture diagnostic solutions

Blood culture diagnostics are at an inflection point where technological innovation, supply chain considerations, and clinical priorities converge to reshape laboratory practice. Conventional culture systems remain central for phenotype-based susceptibility testing, while molecular and automated adjuncts are redefining expectations for speed and diagnostic resolution. These complementary modalities create opportunities for hybrid diagnostic pathways that balance rapid identification with comprehensive susceptibility determination, thereby improving stewardship and patient outcomes. Operationally, laboratories must navigate tariff-related cost pressures, supply chain variability, and the demands of integration and validation when adopting new platforms.

Strategic responses that emphasize interoperability, regional supply resilience, and outcome-focused service models will be most effective in sustaining performance and value. By aligning product portfolios with the nuanced needs of different end users - from bedside point-of-care contexts to high-throughput reference laboratories - vendors and healthcare organizations can enhance diagnostic impact while managing total cost of operation. Looking ahead, collaborative approaches that connect manufacturers, laboratory leaders, and clinical teams will accelerate the translation of technological advances into measurable clinical benefits, supporting safer, faster, and more targeted care for patients with suspected bloodstream infections.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Culture Test Market, by Product

  • 8.1. Consumables
    • 8.1.1. Bottles
    • 8.1.2. Culture Media
    • 8.1.3. Reagent Kits
  • 8.2. Instruments
    • 8.2.1. Analyzers
    • 8.2.2. Automation Systems

9. Blood Culture Test Market, by Technology

  • 9.1. Conventional
  • 9.2. Molecular
    • 9.2.1. Next Generation Sequencing
    • 9.2.2. Polymerase Chain Reaction

10. Blood Culture Test Market, by Test Type

  • 10.1. Automated
  • 10.2. Manual

11. Blood Culture Test Market, by Sample Type

  • 11.1. Plasma
  • 11.2. Whole Blood

12. Blood Culture Test Market, by Mode

  • 12.1. Central Lab
  • 12.2. Point Of Care
    • 12.2.1. Bedside
    • 12.2.2. Portable

13. Blood Culture Test Market, by End User

  • 13.1. Ambulatory Care Centers
    • 13.1.1. Independent Clinics
    • 13.1.2. Physician Offices
  • 13.2. Blood Banks
  • 13.3. Diagnostic Laboratories
    • 13.3.1. Hospital Based Labs
    • 13.3.2. Independent Labs
  • 13.4. Hospitals & Clinics
    • 13.4.1. Secondary Hospitals
    • 13.4.2. Tertiary Hospitals

14. Blood Culture Test Market, by Application

  • 14.1. Bacterial
    • 14.1.1. Gram Negative
    • 14.1.2. Gram Positive
  • 14.2. Fungal
    • 14.2.1. Filamentous Fungi
    • 14.2.2. Yeast
  • 14.3. Mycobacterial

15. Blood Culture Test Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Blood Culture Test Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Blood Culture Test Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Blood Culture Test Market

19. China Blood Culture Test Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Accelerate Diagnostics, Inc.
  • 20.6. Autobio Diagnostics Co. Ltd.
  • 20.7. Becton Dickinson and Company
  • 20.8. bio-Rad Laboratories, Inc.
  • 20.9. bioMerieux SA
  • 20.10. F. Hoffmann-La Roche
  • 20.11. Siemens Healthineers AG
  • 20.12. Sigma-Aldrich
  • 20.13. Sysmex Corporation
  • 20.14. Thermo Fisher Scientific Inc.
  • 20.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD CULTURE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD CULTURE TEST MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLOOD CULTURE TEST MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES BLOOD CULTURE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA BLOOD CULTURE TEST MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLOOD CULTURE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 281. GCC BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. GCC BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 283. GCC BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 284. GCC BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 285. GCC BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. GCC BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 287. GCC BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. GCC BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. GCC BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 290. GCC BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 291. GCC BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. GCC BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 293. GCC BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 294. GCC BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 295. GCC BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 296. GCC BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 297. GCC BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 332. G7 BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 333. G7 BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 334. G7 BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 335. G7 BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 336. G7 BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 337. G7 BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 338. G7 BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. G7 BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. G7 BLOOD CULTURE TEST MARKET